

New agreement between ZymIQ and fjör paves the way for global growth and product innovation

ZymIQ has signed a new agreement with the British cosmetics company fjör Ltd. The new contract marks the beginning of a strengthened collaboration focused on global expansion and product development.

The agreement, which runs for 36 months with the possibility of extension, guarantees ZymlQ a fixed revenue level throughout the period. It replaces the previous agreement between the parties and means that ZymlQ will now manufacture all products in fjör's range as well as be responsible for the development of new products.

fjör (www.fjor.life) is an innovative skincare brand built on biomimetic principles and scientifically developed formulations. The products utilize ZymlQ's enzyme technology and are designed to support the skin's barrier function and promote microbial diversity—key to maintaining a balanced and resilient skin. fjör has received international recognition in leading publications such as Vogue, Financial Times, The Handbook, Esquire, and Stylist.

"Our collaboration is built on a shared commitment to breakthrough science, integrity and purpose. Together, we've created something that goes beyond skincare, products that reflect years of research, mutual trust and a belief in advancing how we care for the skin," says Natalie Enslöw, Founder and CEO of fjör.

"That fjör is now scaling up its operations shows that their products are appreciated by customers around the world. I am delighted to see fjör's continued success and expansion," says Michael Edelborg Christensen, CEO of ZymIQ.

For more information, please contact:

Michael Edelborg Christensen, CEO

Phone +46 727 144 166

Email: michael.christensen@zymiq.com

About ZymIQ

ZymlQ Technology AB (publ) is a life science company headquartered in Lund, Sweden and the parent company of the ZymlQ Group. Subsidiaries include ZymlQ Biopharma AB, Sweden and ZymlQ Animal Health LLC, Virginia, USA. The company is also represented by offices in Singapore and Malaysia. ZymlQ develops, manufactures and sells innovative enzyme-based therapeutic and cosmetic products for the well-being of humans and animals. ZymlQ also conducts pioneering research on future alternatives to antibiotics to combat the global challenge of antibiotic resistance, www.zymiq.com



Attachments

New agreement between ZymIQ and fjör paves the way for global growth and product innovation